Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPennon Regulatory News (PNN)

Share Price Information for Pennon (PNN)

Share Price is delayed by 15 minutes
Get Live Data
513.00    9.50 (1.89%)
Bid:
509.00
Ask:
509.50
Spread: 0.50 (0.098%)
Market Cap: £2.42b
PNN Live PriceLast checked at - London Stock Exchange

Intraday Pennon Share Chart

Board Changes

8 Apr 2025 07:00

RNS Number : 0089E
Pennon Group PLC
08 April 2025
 

The Board of Pennon Group Plc (the "Company") is pleased to announce that Andrea Blance has been appointed as a Non-Executive Director and Chair of the Remuneration Committee of the Company with effect from 8 April 2025. 

Andrea brings extensive risk and regulation expertise and is passionate about developing customer focused commercial strategies, following a long career in Financial Services. She is a Non-Executive Director and Risk Committee Chair at Aviva plc and an Advisory Board Member of The Mentoring Foundation.

Andrea spent her executive career at Legal & General Group plc where she held a range of senior leadership roles including Group Chief Risk Officer and Strategy & Marketing Director. More recently, Andrea has been Risk Committee Chair at Hargreaves Lansdown plc, Senior Independent Director and Remuneration Committee Chair of Vanquis Banking Group plc, Senior Independent Director and Audit Committee Chair of ReAssure plc, and Risk Committee Chair of Scottish Widows plc and Lloyds Banking Group Insurance.

Commenting on the appointment, David Sproul, Chair, said, "On behalf of the entire Board, I look forward to welcoming Andrea to Pennon. Her extensive regulatory experience and strong belief in the positive role that businesses should play delivering for customers and communities, and driving sustainable shareholder value, will be invaluable."

Andrea said, "I am absolutely delighted to have been appointed as Remuneration Chair of Pennon. I look forward to working with the Board and a brilliant team of valued colleagues as we look to deliver for customers and all stakeholders, with an enduring positive impact on the environment and society."

The Company confirms that there is no other information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to these appointments.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUBAKRVKUSRAR
Date   Source Headline
1st Jun 20267:00 amRNSTotal Voting Rights
29th May 20262:06 pmRNSHolding(s) in Company
20th May 20261:48 pmRNSDirector/PDMR Shareholding
14th May 202612:03 pmRNSDirector/PDMR Shareholding
6th May 20262:12 pmRNSAdmission to Trading
1st May 20264:31 pmRNSHolding(s) in Company
1st May 20267:00 amRNSTotal Voting Rights
30th Apr 20263:11 pmRNSHolding(s) in Company
27th Apr 20264:34 pmRNSHolding(s) in Company
24th Apr 20263:29 pmRNSHolding(s) in Company
22nd Apr 20264:30 pmRNSHolding(s) in Company
21st Apr 20261:17 pmRNSDirector/PDMR Shareholding
20th Apr 20264:09 pmRNSHolding(s) in Company
14th Apr 20264:24 pmRNSRescheduled Full-Year Results Date
1st Apr 20267:00 amRNSTotal Voting Rights
20th Mar 20262:06 pmRNSDirector/PDMR Shareholding
10th Mar 20267:00 amRNSTrading Statement
2nd Mar 20267:00 amRNSTotal Voting Rights
23rd Feb 202612:58 pmRNSDirector/PDMR Shareholding
10th Feb 20267:00 amRNSConfirmation of Chief Executive Officer Start Date
5th Feb 202610:58 amRNSHolding(s) in Company
2nd Feb 20267:01 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSBlock listing Interim Review
23rd Jan 20263:21 pmRNSDirector/PDMR Shareholding
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
23rd Dec 20253:29 pmRNSDirector/PDMR Shareholding
23rd Dec 20253:29 pmRNSDirector/PDMR Shareholding
11th Dec 20251:16 pmRNSConfirmed Financial Calendar
9th Dec 20254:01 pmRNSDirector/PDMR Shareholding
9th Dec 20257:00 amRNSPennon Group CEO Transition Arrangements
1st Dec 20253:42 pmRNSEMTN: Publication of Supplementary Prospectus
1st Dec 20257:00 amRNSTotal Voting Rights
27th Nov 20257:00 amRNSHalf Year Results 2025/26
21st Nov 20254:24 pmRNSDirector/PDMR Shareholding
3rd Nov 20257:00 amRNSTotal Voting Rights
22nd Oct 20251:26 pmRNSDirector/PDMR Shareholding
7th Oct 20257:00 amRNSPennon appoints new Non-Executive Director
3rd Oct 20252:19 pmRNSDirector/PDMR Shareholding
2nd Oct 20257:00 amRNSPennon Group appoints Keith Haslett as new CEO
1st Oct 20257:00 amRNSTotal Voting Rights
26th Sep 20257:00 amRNSTrading Statement
23rd Sep 20254:16 pmRNSDirector/PDMR Shareholding
11th Sep 202512:09 pmRNSEMTN Programme: Publication of Final Terms
1st Sep 20257:00 amRNSTotal Voting Rights
28th Aug 20252:44 pmRNSDirector/PDMR Shareholding
22nd Aug 20259:41 amRNSEMTN Programme: Publication of Base Prospectus
20th Aug 20254:15 pmRNSDirector/PDMR Shareholding
1st Aug 20257:01 amRNSTotal Voting Rights
1st Aug 20257:00 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.